Comparative effects of torasemide and furosemide in rats with heart failure

Biochemical Pharmacology

Volumn 75, Issue 3, 2008, Pages 649-659

  Veeraveedu, Punniyakoti T ^a   Watanabe, Kenichi ^a   Ma, Meilei ^a   Thandavarayan, Rajarajan A ^a   Palaniyandi, Suresh S ^a,c   Yamaguchi, Ken'ichi ^b   Suzuki, Kenji ^b   Kodama, Makoto ^b   Aizawa, Yoshifusa ^b  

^a NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aldosterone; Experimental autoimmune myocarditis; Fibrosis; Furosemide; Remodeling; Torasemide

Indexed keywords

ALDOSTERONE SYNTHASE; CARDIAC MYOSIN; COLLAGEN TYPE 3; FUROSEMIDE; POTASSIUM; TORASEMIDE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART MUSCLE FIBROSIS; IMMUNIZATION; MALE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SURVIVAL; URINARY EXCRETION;

ALDOSTERONE SYNTHASE; ANIMALS; COLLAGEN TYPE III; DIURETICS; FUROSEMIDE; HEART FAILURE; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; RATS; RATS, INBRED LEW; SULFONAMIDES; SURVIVAL RATE; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR FUNCTION, LEFT;

EID: 38049043455     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2007.09.026     Document Type: Article

References (42)

1. Haslet C., Chilvers E.R., Hunter J.A.A., and Boon N.A. Davidson's principles and practice of medicine. 18th ed. (1999), Churchill Livingstone, London
2. Abraham W.T., and Schrier R.W. Body fluid volume regulation in health and disease. Adv Intern Med 39 (1994) 23-47
3. Ho K.K., Pinsky J.L., Kannel W.B., and Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22 4A (1993) 6A-13A
4. Brater D.C., Leinfelder J., and Anderson S.A. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 42 (1987) 187-192
5. Murray M.D., Deer M.M., Ferguson J.A., Dexter P.R., Bennett S.J., Perkins S.M., et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med 111 (2001) 513-520
6. Spannheimer A., Goertz A., and Dreckmann-Behrendt B. Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint. Int J Clin Pract 52 (1998) 467-471
7. Cosin J., and Diez J. TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 4 (2002) 507-513
8. Yamato M., Sasaki T., Honda K., Fukuda M., Akutagawa O., Okamoto M., et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ J 67 (2003) 384-390
9. Lopez B., Querejeta R., Gonzalez A., Sanchez E., Larman M., and Diez J. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 43 (2004) 2028-2035
10. Tsutamoto T., Sakai H., Wada A., Ishikawa C., Ohno K., Fujii M., et al. Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure. J Am Coll Cardiol 44 (2004) 2252-2253
11. Kasama S., Toyama T., Hatori T., Sumino H., Kumakura H., Takayama Y., et al. Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. Heart 92 (2006) 1434-1440
12. Cooper Jr. L.T. Pathology of human myocarditis. In: Cooper Jr. L.T. (Ed). Myocarditis-from bench to bedside (2003), Humana press, New Jersey 358
13. Kodama M., Hanawa H., Saeki M., Hosono H., Inomata T., Suzuki K., et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 75 (1994) 278-284
14. Watanabe K., Ohta Y., Nakazawa M., Higuchi H., Hasegawa G., Naito M., et al. Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy. Br J Pharmacol 130 (2000) 1489-1495
15. Veeraveedu P.T., Watanabe K., Ma M., Palaniyandi S.S., Yamaguchi K., Suzuki K., et al. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure. Biochem Pharmacol 74 (2007) 1466-1475
16. Uchida T., Yamanaga K., Nishikawa M., Ohtaki Y., Kido H., and Watanabe M. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol 205 (1991) 145-150
17. Yamaguchi K. Effects of water deprivation on immunoreactive angiotensin II levels in plasma, cerebroventricular perfusate and hypothalamus of the rat. Acta Endocrinol (Copenh) 97 (1981) 137-144
18. Rihal C.S., Nishimura R.A., Hatle L.K., Bailey K.R., and Tajik A.J. Systolic and diastolic dysfunction in patients with clinical diagnosis of dilated cardiomyopathy. Relation to symptoms and prognosis. Circulation 90 (1994) 2772-2779
19. McCurley J.M., Hanlon S.U., Wei S.K., Wedam E.F., Michalski M., and Haigney M.C. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 44 (2004) 1301-1307
20. Seeland U., Kouchi I., Zolk O., Jockenhovel F., Itter G., Linz W., et al. Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats. Eur J Heart Fail 5 (2003) 241-246
21. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., and Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100 (1999) 1311-1315
22. Domanski M., Norman J., Pitt B., Haigney M., Hanlon S., and Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 42 (2003) 705-708
23. Uchida T., Ohtaki Y., Kido H., and Watanabe M. Diuretic profile of a novel loop diuretic torasemide in rats and dogs. Drugs Exp Clin Res 17 (1991) 293-298
24. Uchida T., Hayashi K., Suzuki Y., and Matsumura Y. Effects of torasemide on renal haemodynamics and function in anaesthetized dogs. Clin Exp Pharmacol Physiol 18 (1991) 497-504
25. Ghys A., Denef J., Delarge J., and Georges A. Renal effects of the high ceiling diuretic torasemide in rats and dogs. Arzneimittelforschung 35 (1985) 1527-1531
26. Weber K.T., and Brilla C.G. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83 (1991) 1849-1865
27. Weber K.T., and Eghbali M. Collagen matrix synthesis and degradation in the development and regression of left ventricular hypertrophy. Cardiovasc Rev Rep 12 (1991) 61-69
28. Delcayre C., and Swynghedauw B. Molecular mechanisms of myocardial remodeling: the role of aldosterone. J Mol Cell Cardiol 34 (2002) 1577-1584
29. Weber K.T., Gerling I.C., Kiani M.F., Guntaka R.V., Sun Y., Ahokas R.A., et al. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets 4 (2003) 505-516
30. Mizuno Y., Yoshimura M., Yasue H., Sakamoto T., Ogawa H., Kugiyama K., et al. Aldosterone production is activated in failing ventricle in humans. Circulation 103 (2001) 72-77
31. Silvestre J.S., Robert V., Heymes C., Aupetit-Faisant B., Mouas C., Moalic J.M., et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 273 (1998) 4883-4891
32. Palaniyandi S.S., Nagai Y., Watanabe K., Ma M., Veeraveedu P.T., Prakash P., et al. Chymase inhibition reduces the progression to heart failure after autoimmune myocarditis in rats. Exp Biol Med 232 (2007) 1213-1221
33. Satoh M., Nakamura M., Saitoh H., Satoh H., Akatsu T., Iwasaka J., et al. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci (Lond) 102 (2002) 381-386
34. Yoshida J., Yamamoto K., Mano T., Sakata Y., Nishio M., Ohtani T., et al. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats. Cardiovasc Res 68 (2005) 118-127
35. Katada J., Meguro T., Saito H., Ohashi A., Anzai T., Ogawa S., et al. Persistent cardiac aldosterone synthesis in angiotensin II type 1A receptor-knockout mice after myocardial infarction. Circulation 111 (2005) 2157-2164
36. Silvestre J.S., Heymes C., Oubenaissa A., Robert V., Aupetit-Faisant B., Carayon A., et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 99 (1999) 2694-2701
37. Shinyama H., Yamanaga K., Akira T., Uchida T., Yaguchi M., Watanabe M., et al. Effects of single and repeated administration of torasemide on plasma renin activity and aldosterone concentration in rats. Clin Rep (Kiso to Rinso) 30 (1996) 503-510
38. Uechi M., Matsuoka M., Kuwajima E., Kaneko T., Yamashita K., Fukushima U., et al. The effects of the loop diuretics furosemide and torasemide on diuresis in dogs and cats. J Vet Med Sci 65 (2003) 1057-1061
39. Goodfriend T.L., Ball D.L., Oelkers W., and Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci 63 (1998) PL45-PL50
40. Fortuno A., Muniz P., Ravassa S., Rodriguez J.A., Fortuno M.A., Zalba G., et al. Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats. Hypertension 34 (1999) 138-143
41. Gonzalez A., Lopez B., Querejeta R., and Diez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease?. J Mol Cell Cardiol 34 (2002) 1585-1593
42. Falcao L.M., Pinto F., Ravara L., and van Zwieten P.A. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. J Renin Angiotensin Aldosterone Syst 5 (2004) 121-129